Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor signiWcantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 2, 2012, Pages 213-220

  Simmons, Brett H ^a   Lee, Joseph H ^a   Lalwani, Kush ^b   Giddabasappa, Anand ^b   Snider, Brittany A ^b   Wong, Anthony ^b   Lappin, Patrick B ^b   Eswaraka, Jeetendra ^b   Kan, Julie L ^a   Christensen, James G ^a   Shojaei, Farbod ^a  

^a Oncology Research Unit   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Combination therapy; Lung tumor; MAPK pathway; PI3K pathway

Indexed keywords

CARBOPLATIN; CISPLATIN; CRE RECOMBINASE; GEMCITABINE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; S6 KINASE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPERPLASIA; LUNG ADENOCARCINOMA; LUNG ADENOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CELL LINE, TUMOR; DIPHENYLAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROZYGOTE; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MICE; MICE, MUTANT STRAINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIDONES; PYRIMIDINES; TOR SERINE-THREONINE KINASES;

EID: 84866561464     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1899-6     Document Type: Article

References (27)

1. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619
2. Kuruvilla FG, Schreiber SL (1999) The PIK-related kinases intercept conventional signaling pathways. Chem Biol 6:R129-R136
3. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317:239-242
4. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM (2007) The structure of a human p110alpha/p85alpha complex elucidates the eVects of oncogenic PI3K alpha mutations. Science 318:1744-1748
5. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR (2008) The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet. Chapter 10, Unit 10.11
6. Kullmann F, Hartmann A, Stohr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E (2011) KRAS mutation in metastatic pancreatic ductal adenocarcinoma: Results of a multicenter phase II study evaluating eYcacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in Wrst-line therapy. Oncology 81:3-8
7. Liu X, Jakubowski M, Hunt JL (2011) KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol 135:245-252
8. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243-3248
9. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, Cao TC, Lee CV, Nannini MA, Fuh G, Carano RA, Koeppen H, Yu RX, Forrest WF, Plowman GD, Johnson L (2010) Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28:585-593
10. Castellano E, Downward J (2011) RAS Interaction with PI3K: More than just another eVector pathway. Genes Cancer 2:261-274
11. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430
12. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK (2008) EVective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356
13. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69:4286-4293
14. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
15. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P (2011) Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 18:2686-2714
16. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P (2008) Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr Opin Pharmacol 8:393-412
17. Cheng HSB, Bailey S, Edwards M, HoVman J, Hu Q, Kania R, Knighton DR, Marx MA, Ninkovic S, Sun S, Zhang E (2010) Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. MedChemComm 1:139-144
18. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA Jr, Smith Y, Warmus JS, Tecle H (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 18:6501-6504
19. Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, RaWdi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10:2189-2199
20. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL (2010) MEK inhibitor PD0325901 signiWcantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther 9:1968-1976
21. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA (2011) In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 10:1440-1449
22. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD (2011) Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 68:547-552
23. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM (2010) A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16:2450-2457
24. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924-1937
25. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4:1064-1072
26. SangerInstitute, http://www.sanger.ac.uk/
27. Ritman EL (2011) Current status of developments and applications of micro-CT. Annu Rev Biomed Eng 13:531-552